2014 JAN 13 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Fresh data on Immune System Diseases and Conditions are presented in a new report. According to news reporting out of London, United Kingdom, by NewsRx editors, research stated, "Detection of the Mycobacterium tuberculosis cell wall antigen lipoarabinomannan (LAM) in urine permits diagnoses of tuberculosis (TB) to be made in HIV-infected patients with advanced immunodeficiency. This can be achieved at the point-of-care within just 30 minutes using the Determine TB-LAM, which is a commercially available, lateral-flow urine 'strip test' assay."
Our news journalists obtained a quote from the research from the London School of Hygiene and Tropical Medicine, "The assay has been shown to have useful diagnostic accuracy in patients enrolling in antiretroviral treatment services or in HIV-infected patients requiring admission to hospital medical wards in sub-Saharan Africa. Such patients have high mortality risk and have most to gain from rapid diagnosis of TB and immediate initiation of treatment. However, few studies using this assay have yet been reported and many questions remain concerning the correct use of the assay, interpretation of results, the role of the assay as an add-on test within existing diagnostic algorithms and the types of further studies needed. In this paper we address a series of questions with the aim of informing the design, conduct and interpretation of future studies. Specifically, we clarify which clinical populations are most likely to derive benefit from use of this assay and how patients enrolled in such studies might best be characterised. We describe the importance of employing a rigorous microbiological diagnostic reference standard in studies of diagnostic accuracy and discuss issues surrounding the specificity of the assay in different geographical areas and potential cross-reactivity with non-tuberculous mycobacteria and other organisms. We highlight the importance of careful procedures for urine collection and storage and the critical issue of how to read and interpret the test strips."
According to the news editors, the research concluded: "Finally, we consider how the assay could be used in combination with other assays and outline the types of studies that are required to build the evidence base concerning its use."
For more information on this research see: Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. Bmc Infectious Diseases, 2013;13():407. (BioMed Central - www.biomedcentral.com/; Bmc Infectious Diseases - www.biomedcentral.com/bmcinfectdis/)
Our news journalists report that additional information may be obtained by contacting S.D. Lawn, Dept. of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. Additional authors for this research include K. Dheda, A.D. Kerkhoff, J.G. Peter, S. Dorman, C.C. Boehme and M.P Nicol (see also Immune System Diseases and Conditions).
Keywords for this news article include: London, Europe, HIV/AIDS, Treatment, RNA Viruses, Retroviridae, United Kingdom, HIV Infections, Infectious Disease, Vertebrate Viruses, Primate Lentiviruses, Gram Positive Bacteria, Mycobacterium Infections, Opportunistic Infections, Actinomycetales Infections, Mycobacterium Tuberculosis, Viral Sexually Transmitted Diseases.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC